Navigation Links
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride
Date:6/8/2009

NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and weight after two years of treatment.

In the study, 58% of patients treated with liraglutide 1.8 mg once daily reached and maintained the ADA's blood sugar target of A1C less than 7% versus 37% of patients treated with glimepiride 8 mg once daily.

"The fact that liraglutide continues to effectively lower blood sugar after two years of treatment is consistent with its other long-term clinical benefits such as continued reductions in fasting blood sugar and weight," said, Dr. Alan Garber, Baylor College of Medicine, Houston, a LEAD(TM) 3 principal study investigator. "Even with available treatments, many type 2 diabetes patients still struggle to control their blood sugar, while losing weight. Liraglutide represents an important advance for these patients."

The LEAD(TM) 3 extension study also documented that treatment with liraglutide leads to early and lasting weight loss. Many currently available diabetes treatments lead to weight gain, a concern for type 2 diabetes patients, most of whom are already overweight. After two years of treatment with 1.8 mg of liraglutide, mean body weight decreased significantly (-2.7 kg) compared to overall weight increase in the glimepiride group (+1.1 kg).

Hypoglycemia is a condition where blood sugar levels become too low. Minor hypoglycemia was more than six times less frequent in the liraglutide treatment groups compared with the glimepiride group.

About LEAD(TM) 3 Extension

The LEAD(TM) 3 Extension compared the efficacy and safety of liraglutide (1.8 mg and 1.2 mg, once daily) to glimepiride (8 mg, once daily) in patients with type 2 diabetes. Patients were treated previously with diet/exercise or low doses of one oral antidiabetic drug (OAD). The trial had a 52-week randomized, double-blind period followed by the one year extension; 59% entered the extension period of the trial and 43% of these patients completed the full two-year study period.

LEAD(TM) 3: two-year data

    Two years                Liraglutide       Liraglutide       Glimepiride
     monotherapy             1.8 mg, QD        1.2 mg, QD        8 mg, QD
                             N=154             N=149             N=137

    Diabetes duration,
     years at baseline         5.0                5.0              5.0

    Previous treatment:
    % diet/exercise             35%                38%              34%
    % OAD monotherapy           65%                62%              66%

    A1C % at baseline          8.1                8.1              8.0

    BMI, kg/m(2) at
     baseline                   33                 33               33

    Change in A1C% from
     baseline                 -1.1               -0.9             -0.6

    Change in A1C%  from
     baseline (in
     patients with <3
     years' duration of
     diabetes)                -1.4               -1.1             -0.7

    % A1C <7.0%                 58                 53               37

    Change FPG (Fasting
     Plasma Glucose)
     mg/dL from baseline       -27                -24               -6

    Weight change, kg
     from baseline            -2.7               -2.1              1.1

    Minor hypoglycemic
     events/patient/year      0.23               0.21             1.76

Safety and tolerability of liraglutide

The rate of minor hypoglycemia was statistically significantly lower with both liraglutide dose groups compared to the glimepiride-treated group. The most common gastrointestinal-related adverse events were nausea, diarrhea and vomiting, and most were transient. Other adverse events reported included flu-like symptoms.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) program comprises five randomized, controlled, double-blinded studies plus one open-label head-to-head study against exenatide and involved more than 4,000 patients with type 2 diabetes in 40 countries.

About Liraglutide

Once-daily liraglutide is the first human Glucagon-Like Peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when blood sugar levels are high. Weight loss with liraglutide is attributed to the fact that it slows gastric emptying and leads to increased satiety after meals. Liraglutide is naturally broken down in the body and does not require renal excretion.

On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration (FDA) in the U.S., as well as a marketing authorization application to the European Medicines Agency (EMEA), for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 14, 2008.

On April 23, 2009, Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the EMEA adopted a positive opinion, recommending marketing authorization of liraglutide for treatment of type 2 diabetes in Europe.

In the U.S., a regulatory decision is pending.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Needy Women and Children in Oakland County Get Big Boost for Free Health Care With Donation of Two-Year Lease for Chrysler 300C
2. Nyer Medical Group, Inc. Announces Sale of Companys Florida Medical-Surgical Division; Pharmacy Division Awarded Two-Year Preferred Supplier Contract
3. Hearings Set for Monday as Part of Two-Year Democratic Process to Unite the Strength of California Long-Term Care Workers to Improve Their Lives and Better Serve Their Clients
4. IASIS Healthcare and Precyse Solutions Sign Two-Year Consulting Agreement
5. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
6. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
7. ECLIPSE data on effects of Otsukas investigational novel treatment, Tolvaptan
8. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
9. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
10. Accentia announces investigational new drug application for Revimmune for refractory MS
11. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... advisory services for healthcare compliance program management, will showcase a range of technology ... Association for Assisted Living (NCAL) Convention and Expo to be held October 14–18, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical Services, ... solutions for injectable drug administration, today shared the results ... Adapter for improving the intradermal administration of polio vaccines. ... Vaccination Summit in May 2017 by Dr. Ondrej ... Department, World Health Organization (WHO), and recently published in ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
Breaking Medicine Technology: